IL2RA and cancer: Surprisingly, testing of these anti-PD-L1 variants in a MLR revealed increased CD8 T cell activation potential for αPDL1GE > αPDL1WT ≥ αPDL1NG determined by surface expression of CD25 and CD137, proliferation as well as cytotoxicity against cancer cells.